Compare TransMedics Group Inc (TMDX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Ultra Short Bond ETF — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Vanguard Ultra Short Bond ETF trades at $49.6. The key difference: TransMedics Group Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| TMDX | VUSB | |
|---|---|---|
Market Cap | $3.06B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $150.42 | $50.03 |
52-Week Low | $61.99 | $49.55 |
Enterprise Value | $3.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
VUSB trades at $49.595 with minimal daily movement, showing a slight decline of 0.01%. The technical picture is bearish with moving averages signaling selling pressure, though oscillators suggest potential short-term recovery. Recent dividend distributions of $0.17-0.18 per share demonstrate consistent income generation. Market sentiment is influenced by Federal Reserve interest rate expectations favoring short-term bonds.
The outlook remains cautious with bearish technical indicators offset by positive sentiment around short-term bond strategies. Investment opportunity lies in the ETF's defensive positioning amid potential rate hikes, while risks include interest rate sensitivity and market volatility. The stock presents a conservative income play in uncertain monetary policy environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
